Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Description
This study will include a Phase 1 dose-finding portion (Cohorts A and B) and a four-arm expansion portion. The primary objectives of the study are to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-8800 administered orally in participants with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML) and to assess the safety and tolerability of H3B-8800 as a single agent administered orally once daily on a 5 days on/9 days off repeated dosing schedule in 28-day cycles in participants with MDS, AML, or CMML.
Study Start Date
August, 01 2016
Estimated Completion Date
March 2019
Interventions
- Drug: H3B-8800
Study ID
Eisai Inc. -- H3B-8800-G000-101
Status
Unknown
Trial ID
Study Type
Interventional
Trial Phase
Phase 1
Enrollment Quota
110
Sponsor
Eisai Inc.
Inclusion Criteria
-
1. Confirmed diagnosis of Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic
Leukemia (CMML), or Acute Myeloid Leukemia (AML).
2. The participant must meet the following criteria relevant to their specific diagnosis:
1. Participants with AML must either refuse or not be considered candidates for
intensive induction chemotherapy. Previously treated participants should have
evidence of persistent or recurrent AML in the peripheral blood and/or bone
marrow. Participants must have white blood cell (WBC) < 15 x 10^9cells/L.
2. For International Prognostic Staging System (IPSS) high-risk or intermediate-2
MDS, participants must be intolerant of hypomethylating agents or not have
responded to 4 treatment cycles of decitabine or 6 treatment cycles of
azacitidine, or must have progressed at any point after initiation of a
hypomethylating agent.
3. For IPSS intermediate-1 or low-risk MDS, participants must be transfusion
dependent for red blood cells or platelets (as determined by instructional
practices or local standard of care). Participants who are red blood cell
transfusion dependent must also have failed erythropoiesis stimulating agents
(primary resistance or relapse after a response) or have serum erythropoietin
(EPO) levels > 500 U/L.
4. For CMML, participants must have been treated with at least one prior therapy
(hydroxyurea or an hypomethylating agent [HMA]).
3. Peripheral Blood Samples:
1. Cohort A: Screening visit peripheral blood must be available for retrospective
analysis of spliceosome mutations of interest.
2. Cohort B and Expansion: Screening visit peripheral blood must be submitted for
central analysis at a sponsor-designated laboratory to identify spliceosome
hotspot mutations in SF3B1, SRSF2, U2AF1, mutations in ZRSR2, and SRSF2 deletion
including amino acid P95.
4. Male or female, age ? 18 years old at the time of consent.
5. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
6. Adequate baseline organ function:
1. Serum creatinine ? 1.7 mg/dL or calculated creatinine clearance ? 50 mL/min per
the Cockcroft and Gault formula
2. Direct bilirubin ? 1.5 x upper limit of normal (ULN)
3. c. Aspartate aminotransferase (AST) and alanine transaminase (ALT) ? 3.0 x ULN
4. Albumin ? 2.5 mg/dL
8. Written informed consent.
Exclusion Criteria
-
1. Females who are breastfeeding or pregnant.
2. Diagnosis of a core binding factor leukemia (t(821), t(1616) or inv(16)).
3. Participant is candidate for hematopoietic stem cell transplants at the time of
enrollment.
4. Family history of Leber Hereditary Optic Neuropathy, Autosomal Dominant Optic Atrophy,
Late-Onset Retinal Degeneration, Familial Dysautonomia or other hereditary
mitochondrial disease, unless the causative mutation(s) in the family have been
determined and the participant has tested negative for the mutation(s).
5. Known prior or current retinal or optic nerve disease (eg, Retinitis Pigmentosa,
diabetic retinopathy, optic neuritis) based on screening ophthalmology assessment for
eligibility.
6. Corrected vision is worse than 20/40 unless due to cataracts.
7. Vitamin B12, folate or vitamin A deficiency. Rescreening following repletion therapy
is acceptable.
8. Use of concomitant medications with evidence for an association with drug-induced
mitochondrial optic neuropathy including systemic administration of ethambutol,
chloramphenicol, linezolid, erythromycin, streptomycin, and zidovudine.
9. Prior exposure to cisplatin, 5-fluorouracil, tamoxifen, and/or MEK inhibitors within 3
months of enrollment and/or ethambutol and/or hydroxychloroquine within 12 months.
10. Use of concomitant medications that are known to be strong inhibitors or inducers of
CYP3A4 enzyme unless participant can discontinue or switch medications.
11. Received treatment with chemotherapy, wide-field radiation, or anti-cancer biologic
therapy including investigational agents within 14 days of study entry.
12. An active malignancy and/or cancer history for at least 2 years with the exception of
non-melanoma skin cancer, carcinoma in situ, cervical intraepithelial neoplasia,
organ-confined prostate cancer with no evidence of progressive disease.
13. Clinically severe cardiovascular disease or clinically significant electrocardiogram
(ECG) abnormality.
14. Uncontrolled, clinically significant pulmonary disease.
15. Known active or suspected central nervous system (CNS) leukemia.
16. Uncontrolled intercurrent illness.
17. Known history of human immunodeficiency virus (HIV), or active Hepatitis B or C.
18. Cardiac troponin (cTn) levels above the upper limit of normal
Gender
All
Ages
18 Years and older
Accepts Healthy Volunteers
No
Study Locations and Contact Information (21)
Study Location | Distance | Name | Phone | |
---|---|---|---|---|
Beth Israel Deaconess Medical Center - Boston, Massachusetts | 2.4 miles | None | None | None |
Dana Farber Cancer Institute - Boston, Massachusetts | 2.4 miles | None | None | None |
Dana Farber Cancer Institute - Boston, Massachusetts | 2.4 miles | None | None | None |
Massachusetts General Hospital - Boston, Massachusetts | 3.2 miles | None | None | None |
Memorial Sloan Kettering Memorial Hospital - New York, New York | 187.1 miles | None | None | None |
Memorial Sloan Kettering Memorial Hospital - New York, New York | 187.1 miles | None | None | None |
Roswell Park Cancer Insitute - Buffalo, New York | 397.2 miles | None | None | None |
Roswell Park Cancer Insitute - Buffalo, New York | 397.2 miles | None | None | None |
Cleveland Clinic Cancer Center - Cleveland, Ohio | 544.9 miles | None | None | None |
Cleveland Clinic Cancer Center - Cleveland, Ohio | 544.9 miles | None | None | None |
Karmanos Cancer Institute - Detroit, Michigan | 611.5 miles | None | None | None |
Karmanos Cancer Institute - Detroit, Michigan | 611.5 miles | None | None | None |
Sarah Cannon Research Institute - Nashville, Tennessee | 942.8 miles | None | None | None |
Sarah Cannon Research Institute - Nashville, Tennessee | 942.8 miles | None | None | None |
Moffitt Cancer Center - Tampa, Florida | 1,178.7 miles | None | None | None |
The University of Texas MD Anderson Cancer Center - Houston, Texas | 1,609.9 miles | None | None | None |
The University of Texas MD Anderson Cancer Center - Houston, Texas | 1,609.9 miles | None | None | None |
Colorado Blood Cancer Institute - Denver, Colorado | 1,766.9 miles | None | None | None |
Fred Hutchinson Cancer Research Center - Seattle, Washington | 2,490.2 miles | None | None | None |
Fred Hutchinson Cancer Research Center - Seattle, Washington | 2,490.2 miles | None | None | None |
Stanford Cancer Center - Stanford, California | 2,694.5 miles | None | None | None |